Akums Drugs IPO - GMP, Subscription, Price, Dates & Financial Details
Akums Drugs IPO has successfully completed its IPO process and is now listed on the NSE and BSE. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹1,857 Crore, comprising a fresh issue of 1.00 Crore equity shares aggregating to ₹680.00 Crore and an offer for sale (OFS) of 1.73 Crore equity shares aggregating to ₹1,176.74 Crore by the existing shareholders.
The Akums Drugs IPO remained open for subscription from July 30, 2024, to August 01, 2024. The basis of allotment was finalized on August 02, 2024, and the company's shares were listed on the NSE and BSE on August 06, 2024.
The company had fixed the price band at ₹646 to ₹679 per share, with a lot size of 22 shares. Retail investors were required to make a minimum investment of ₹14,938 (based on the upper price band) to apply for one lot.
The IPO also included a reservation of 243,902 equity shares for eligible employees, who received a discount of ₹64 per share.
MUFG Intime India Private Limited served as the registrar to the issue. Axis Bank Limited, Citigroup Global Markets India Private Limited, ICICI Securities Limited, and Ambit Private Limited acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Akums Drugs and Pharmaceuticals Limited is now a publicly listed company on the NSE and BSE. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
- Price Band
- ₹ 646 – 679
- Lot Size
- 22
- Issue Size
- ₹1,856.74 Cr
- Minimum Investment
- ₹ 14,938 (22 Shares)
- Listing Date
- 06 August 2024
Current GMP
₹43 (+6.33%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a leading pharmaceutical contract development and manufacturing organization (CDMO) providing a comprehensive range of products and services in India and internationally.
The company offers end-to-end solutions for product development, manufacturing, research and development (R&D) of formulations, regulatory dossier preparation, and submission, along with other testing services. Akums is also involved in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, Akums produces a variety of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears. The company has commercialised 4,025 formulations in over 60 dosage forms and, in 2023, manufactured formulations for 26 of India's top 30 pharmaceutical companies by revenue. Akums operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually as of September 30, 2023.
Akums Drugs IPO Promoters
- Sanjeev Jain
- Sandeep Jain
- Akums Master Trust
Promoters Holding
Holding Pre Issue
84.94%
Holding Post Issue
0.00%
Akums Drugs IPO Objective
The Company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment/ prepayment of indebtedness of the company and its Subsidiaries
- Funding incremental working capital requirements of the company
- Pursuing inorganic growth initiatives through acquisitions
- General corporate purposes.
Akums Drugs and Pharmaceuticals Limited Address / Contact Details
Akums Drugs and Pharmaceuticals Limited
304, Mohan Place,
LSC Saraswati Vihar,
Delhi - 110 034
Phone: +91 11 6904 1000
Email: cs@akums.net
Website: http://www.akums.in
IPO Snapshot
Book Running Lead Managers
- Axis Bank Limited
- Citigroup Global Markets India Private Limited
- ICICI Securities Limited
- Ambit Private Limited
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Akums Drugs IPO?
Akums Drugs IPO is a Book-building IPO with a total issue size of ₹1856.74 crore. The Akums Drugs IPO price band is ₹646 to 679 per share. The Akums Drugs IPO subscription opens on Tue, Jul 30, 2024, and closes on Thu, Aug 1, 2024. The Akums Drugs IPO will be listed on the NSE,BSE. MUFG Intime India Private Limited is the registrar for the Akums Drugs IPO.
When will the Akums Drugs IPO open for subscription?
The Akums Drugs IPO opens on Tue, Jul 30, 2024 and closes on Thu, Aug 1, 2024
What is Akums Drugs IPO Price Band?
Akums Drugs IPO Price Band is ₹646 to 679 per share.
What is Akums Drugs IPO Lot Size?
Akums Drugs IPO lot size is 22 shares, Retail investors need a minimum investment of ₹14938 based on the upper price band
What is the minimum investment for Akums Drugs IPO?
The minimum investment for Akums Drugs IPO is ₹14938, based on one lot of 22 shares at the upper price band of ₹679 per share.
How to apply for Akums Drugs IPO?
Investors can apply for the Akums Drugs IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Thu, Aug 1, 2024. The application amount remains blocked until the Akums Drugs IPO allotment is finalized.
What is Akums Drugs IPO Issue Size?
Akums Drugs IPO issue size is ₹1856.74 crores.
What is the Akums Drugs IPO Allotment Date?
Akums Drugs IPO allotment date is Fri, Aug 2, 2024.
Who is the Akums Drugs IPO Registrar?
The registrar for Akums Drugs IPO is MUFG Intime India Private Limited. Investors can go to MUFG Intime India Private Limited website to check Akums Drugs IPO allotment status, refund processing, and other IPO-related information.
What is the Akums Drugs IPO GMP?
The Akums Drugs IPO GMP (Grey Market Premium) is ₹43 as of Tue, Aug 6, 2024. Based on the upper price band of ₹679 per share, the estimated Akums Drugs IPO listing price is ₹722, indicating a potential listing gain of approximately 6.33% over the issue price.
Who is the Akums Drugs IPO Lead Manager?
The book-running lead managers (BRLMs) for the Akums Drugs IPO are Citigroup Global Markets India Private Limited, ICICI Securities Limited, and Ambit Private Limited. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Akums Drugs IPO Red Herring Prospectus (RHP).